In this episode, Dr. Shanmugam discusses "A Randomized, Placebo-controlled Phase 3 Extension Trial of Long-term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus", a three-year long-term study designed to understand the safety of anifrolumab in patients with systemic lupus erythematosus (SLE). This study, which was recently published in "Arthritis & Rheumatology", represents the longest placebo-controlled clinical trial performed in SLE to date. She is joined by our guest, Dr. Richard Furie, Chief of the Division of Rheumatology at Northwell Health in New York and co-author of the paper.